0.00
—
Close of 6 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Statera Biopharma
Its shares trade under the ticker STAB. It has been listed since 21 July 2006. In the fiscal year to 31 December 2021, it reported revenue of $1.5m and a net loss of $101.8m. At that date it held total assets of $21.2m and shareholders' equity of −$1.6m.
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is headquartered in Fort Collins, Colorado. The company went IPO on 2006-07-21. The firm is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. The company has platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. The firm is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. The company has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 21 Jul 2006
- Employees
- 46
- Website
- staterabiopharma.com ↗
Leadership
Pay as last reported
- Mr. Michael HandleyChairman of the Board, President, Chief Executive Officer, since 2021$2.9m
- Mr. Christopher ZoshInterim Chief Financial Officer, Executive Vice President - Finance, Interim Chief Accounting Officer$121,440
- Mr. Robert BuckheitChief Technology Officer
- Dr. Andrei GudkovVice President - Global Development$26,055
- Dr. Satish ChandranIndependent Director
- Dr. Blake HawleyIndependent Director
- Mr. John KallassyIndependent Director
- Dr. Uday SaxenaIndependent Director
- Ms. Nichol OchsnerExecutive V.P. Investor Relations & Corporate Communications, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company has a proprietary platform for rebalancing the immune system and restoring homeostasis.
- Developing therapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers.
- Has clinical programs for Crohn's disease, hematology, pancreatic cancer, and COVID-19.
Weaknesses
- Company has only 46 employees.
- IPO occurred in 2006, indicating a long history but potentially limited recent growth.
- Operates as a clinical-stage biopharmaceutical company with no mention of commercial products.
Opportunities
- Potential to expand clinical programs into new disease areas using the proprietary platform.
- Growing focus on immunotherapies for autoimmune and infectious diseases could attract investment.
- Development of therapies targeting emerging viruses may align with global health trends.
Threats
- Clinical-stage companies face high risks of trial failures and regulatory hurdles.
- Dependence on a single proprietary platform may limit diversification.
- Competition in biotechnology sector is intense with many established players.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.